Skip to main content

Chronic Leg Ulcer

1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

SoftOx
SoftOxNorway - Fornebu
1 program
1
SoftOx Biofilm EradicatorPhase 11 trial
Active Trials
NCT05710094Completed28Est. Aug 2022
Purdue Pharma
Purdue PharmaCT - Stamford
1 program
Locally sourced compression therapyN/A1 trial
Active Trials
NCT03404297Completed30Est. Dec 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
SoftOxSoftOx Biofilm Eradicator
Purdue PharmaLocally sourced compression therapy

Clinical Trials (2)

Total enrollment: 58 patients across 2 trials

NCT05710094SoftOxSoftOx Biofilm Eradicator

Safety and Tolerability of Single and Multiple Doses of SoftOx Biofilm Eradicator (SBE) in Chronic Leg Wounds

Start: Oct 2021Est. completion: Aug 202228 patients
Phase 1Completed
NCT03404297Purdue PharmaLocally sourced compression therapy

Compression Therapy for Leg Ulcers and Kaposi Sarcoma in Western Kenya

Start: Mar 2018Est. completion: Dec 201930 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.